On 14 April 2015, the French National Assembly adopted the new bill on modernization of the health system.
The bill was presented for the first time on 15 October 2014 before the Council of Ministers, and it is intended to improve the conditions for national health services.
The French government wants to innovate in the organisation of health care services, in particular for prevention matters and improving individuals rights. The new bill contains several provisions aimed to reform the old French health system such as:
- The right for people who had cancer to apply for bank loans without mentioning their former illness (so-called “droit à l’oubli”)
- Giving a better nutritional information on the food products with a logo and a colour code
- Increasing the applicable fines up to 45,000 euros to prevent alcoholism of young people
- The prohibition to smoke in cars in presence of children passengers, and the implementation of a neutral cigarette box (no logo)
- The experimentation of public drug consumption rooms for 6 years
- The improvement of the HIV detection with auto-tests available in pharmacies
- Helping youth health formation, facilitating access to emergency contraceptive pills and removing the 7-day waiting period imposed to women going through abortions
- Developing the direct payment of health services to health professionals (doctors) by the French NHS (Sécurité Sociale) and health care insurers in 2017 (so-called “tiers payant”)
- Creating the possibility of class actions in matters involving damages to people health
- Introducing a presumption of consent to organ donations for all adults and a possibility to express their opposition
- The possibility for the High Health Authority (HAS) to organise early consultations at the request of companies developing innovative pharmaceutical products with a new mechanism of action and for an insufficiently covered medical need. This would be implemented before the start of clinical trials.
- The right for the drug pricing committee (CEPS) to enter into framework agreements with bodies representing patients, enabling them to consult and exchange information on the setting of prices of reimbursed medicines and other health products. These agreements would be made for renewable three-year periods. The organisations can apply for participation to the negotiations of the agreements or to become party to an agreement in force.
- •The obligation for the marketing authorisation (authorisation de mise sur le marché) holder, and not only for the exploiting company (exploitant) to ensure an appropriate and continuous supply of medical products.
The French Health Minister Marisol Touraine declared that the bill should be adopted by the French Parliament and entered into force by the end of the year.